Proton pump inhibitors do not contribute to dementia or Alzheimer’s disease
Proton pump inhibitors (PPIs) are medications used to treat digestive problems such as ulcers and reflux disease by reducing the body's production of the acid that helps us digest food. Ulcers are sores that develop on the lining of our digestive system; when they develop in the upper part of the small intestine they are called "duodenal ulcers." Reflux disease is a condition in which stomach acid or other fluids in the digestive system irritate our food pipe, also known as the esophagus.
Recently, safety questions about these medications have been raised in several studies. These studies suggested that PPIs increased the risk for dementia and Alzheimer's disease in people 75-years-old or older. Noting that the prescription of PPIs is on the rise among middle-aged and older adults, a team of researchers designed a new study to examine PPIs and the risk of dementia, mild cognitive impairment, and Alzheimer's disease. They published their study in the Journal of the American Geriatrics Society. The researchers also examined whether people with mild cognitive impairment who took PPIs were at higher risk for developing dementia or Alzheimer's disease.
The researchers examined information from the National Alzheimer's Coordinating Center (NACC) database for 2005 through 2015. Data came from people who were 50-years-old or older and had either normal brain function (their scores on cognitive tests were normal and they could perform everyday activities) or mild cognitive impairment (their cognitive test scores were lower than normal but they could still perform everyday activities). The researchers monitored whether the participants took PPIs, how often they took them, and which PPIs they used.
Of the 10,486 participants:
- More than 8 percent said they always used PPIs.
- More than 18 percent used them occasionally.
- More than 73 percent never used PPIs.
The people who always or occasionally used PPIs were significantly older than those who didn't. What's more, compared to the non-PPI users, a significantly higher percentage of those who took PPIs regularly or occasionally had heart disease, diabetes, hypertension, stroke or transient ischemic attack (TIA, a brief stroke-like attack that generally ends quickly but still requires immediate medical attention), and depression.
A higher percentage of people who took PPIs regularly or occasionally also took a higher percentage of anticholinergic medications, which are often used to treat incontinence, depression, and sleep disorders. These medications have been linked to cognitive impairment, too.
There was a decreased risk of cognitive decline among the people who used PPIs regularly, as well as among people who used them occasionally, said the researchers. The researchers cautioned that clinical trials would be needed to confirm whether PPIs were linked to a greater risk of cognitive decline.
This summary is from "Proton Pump Inhibitors and Risk for Mild Cognitive Impairment and Dementia." It appears online ahead of print in the May 2017 issue of the Journal of the American Geriatrics Society. The study authors are Felicia C. Goldstein, PhD; Kyle Steenland, PhD; Liping Zhao, MSPH; Whitney Wharton, PhD; Allan I. Levey, MD, PhD; and Ihab Hajjar, MD, MS.
About the Health in Aging Foundation
This research summary was developed as a public education tool by the Health in Aging Foundation. The Foundation is a national non-profit established in 1999 by the American Geriatrics Society to bring the knowledge and expertise of geriatrics healthcare professionals to the public. We are committed to ensuring that people are empowered to advocate for high-quality care by providing them with trustworthy information and reliable resources. Last year, we reached nearly 1 million people with our resources through HealthinAging.org. We also help nurture current and future geriatrics leaders by supporting opportunities to attend educational events and increase exposure to principles of excellence on caring for older adults. For more information or to support the Foundation's work, visit http://www.HealthinAgingFoundation.org.
About the Journal of the American Geriatrics Society
Included in more than 9,000 library collections around the world, the Journal of the American Geriatrics Society (JAGS) highlights emerging insights on principles of aging, approaches to older patients, geriatric syndromes, geriatric psychiatry, and geriatric diseases and disorders. First published in 1953, JAGS is now one of the oldest and most impactful publications on gerontology and geriatrics, according to ISI Journal Citation Reports®. Visit wileyonlinelibrary.com/journal/JGS for more details.
About the American Geriatrics Society
Founded in 1942, the American Geriatrics Society (AGS) is a nationwide, not-for-profit society of geriatrics healthcare professionals that has–for 75 years–worked to improve the health, independence, and quality of life of older people. Its nearly 6,000 members include geriatricians, geriatric nurses, social workers, family practitioners, physician assistants, pharmacists, and internists. The Society provides leadership to healthcare professionals, policymakers, and the public by implementing and advocating for programs in patient care, research, professional and public education, and public policy. For more information, visit AmericanGeriatrics.org.
Daniel E. Trucil
Related Journal Article